tirzepatide approval date FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes FDA Approves Diabetes Drug Tirzepatide

Whilst generally well tolerated, allergic reactions to tirzepatide injection can occur, ranging from mild local injection site reactions to severe systemic hypersensitivity

Add one

Consult with a qualified healthcare professional prior to using this product, especially if you are pregnant, nursing, have a diagnosed medical condition, or are taking a prescription medication

Today, many people also use them for weight loss

With respect to GLP-1 agonists, for most people the risks of common-but-benign and serious-but-rare side effects are significantly outweighed by the serious known risks of obesity and adverse metabolic states that are common side effects of bipolar medications

Jan 2015;3(1):2-7